Patents by Inventor Simon Edward Ward

Simon Edward Ward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4-Quinolinemethanol derivatives as purine receptor antagonists (1)
    Patent number: 6583156
    Abstract: Use a compound of formula (I) wherein: R1 is hydrogen or alkyl; R2 and R3 are independently selected from hydrogen, alkyl, aryl and heterocyclyle or together may form a ring or R1 and R2 or R3 together may form an oxygen-containing, optionally fused ring pharmaceutically acceptable salts or prodrugs thereof, with the proviso that where R1 and R4 to R9 are hydrogen, R2 or R3 is not 3-methoxy-4-benzyloxyphenyl or 2-dimethylaminoethoxymethyl, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial.
    Type: Grant
    Filed: May 16, 2001
    Date of Patent: June 24, 2003
    Assignee: Vernalis Research Limited
    Inventors: Roger John Gillespie, Joanne Lerpiniere, Suneel Gaur, David Reginald Adoms, Lars Jacob Stray Knutsen, Simon Edward Ward
  • 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
    Patent number: 6531511
    Abstract: The use of a compound of formula (1), as disclosed in the specification, wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl and aryl, or pharmaceutically acceptable salts thereof, with the proviso that wherein R1 to R4 and R6 are hydrogen, R5 is not selected from CH2CH2NHSO2CH3, CH2CH2NHSO2CF3 and methyl substituted by SO2NH2, SO3H, PO3H2, CONHOH or a heterocyclic group selected from formulae (a), (b), (c), (d) and (e) in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: March 11, 2003
    Assignee: Vernalis Research Limited
    Inventors: Roger John Gillespie, Nathaniel Julius Thomas Monck, Andrew James Bird, Simon Edward Ward
  • 1-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
    Patent number: 6500866
    Abstract: Compounds of 1-(adamantyl) amidine and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmittion.
    Type: Grant
    Filed: September 11, 2000
    Date of Patent: December 31, 2002
    Assignee: Vernalis Research Limited
    Inventors: Roger John Gillespie, Michael Fredrick Snape, Simon Edward Ward